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 Acute coronary syndrome (ACS) continues to be the most common cause of death in the 
United States, and nearly every 34 seconds one American has a coronary event. Based on 12-
lead electrocardiogram (ECG) findings myocardial infarction (MI) patients are treated, according 
to guidelines, emergently with reperfusion therapy if presenting with ST elevation myocardial 
infarction (STEMI), versus delayed revascularization if presenting with non-ST elevation 
myocardial infarction (NSTEMI). However, the evidence shows there is a lack of recognition of 
which patients require immediate catherization utilizing the current guidelines. In recent years, 
approximately 70% of acute MI (AMI) patients are classified as NSTEMI. Furthermore, it has 
been observed that approximately 30% of NSTEMI patients have total occluded coronary 
arteries (TOCA) on angiography yet face a delayed intervention approach that contributes to 
worsened clinical outcomes.  
The current STEMI/NSTEMI paradigm lacks the accuracy in triaging patients who have 
a suspected acute coronary occlusion (ACO) or near occlusion, with insufficient collateral 
circulation, whose myocardium is at imminent risk of irreversible infarction without immediate 
reperfusion. A more recent emerging paradigm to determine who warrants immediate 
reperfusion is ACO-MI/Non-ACO-MI or Occlusion Myocardial Infarction (OMI) versus Non-
Occlusion Myocardial Infarction (NOMI) for short. To answer whether the OMI/NOMI 
paradigm was superior to STEMI/NSTEMI in evaluating ACS patients, a literature review was 
conducted primarily utilizing the database PubMed, and certain full-text articles were obtained 
through Augsburg University’s interlibrary loan system. Overall, literature shows limitations of 
the current STEMI/NSTEMI paradigm and shows that OMI/NOMI paradigm has superior 
diagnostic accuracy and earlier recognition abilities for treating patients that present with ACS. 





Acute coronary syndrome (ACS) continues to be the leading cause of death in Americans 
with a coronary event occurring every 34 seconds [1]. The diagnosis and management of 
suspected ACS patients is done through primarily risk stratifying according to ECG findings 
showing either ST segment elevations (STEMI), or non-ST segment elevations (NSTEMI) to 
determine use of early invasive management or early conservative strategy. In addition to ECG 
findings, history of presenting symptoms and biochemical markers of myocardial necrosis are 
also utilized to further classify suspected ACS patients. The current STEMI/NSTEMI paradigm 
in treating presentations of ACS can be traced back to the early 2000s, in part due to research 
revealing that the subset of patients presenting with ST elevations on their ECGs had mortality 
benefits versus those who did not show ST segment elevations when given thrombolytics [2]. 
Although the research should have been taken as an initial step into risk stratifying patients to 
determine use of emergent reperfusion therapy, the outcome was an almost synonymous 
association between the surrogate ECG marker of STE and acute coronary occlusions (ACO). 
Historically, the STEMI/NSTEMI guideline’s development and refinement have been done 
through flawed methodology, failing to utilize angiographic evidence to accurately determine 
which patients had occluded arteries with imminent irreversible myocardial damage requiring 
emergent reperfusion therapy [2-4]. With the current paradigm, the guidelines advocate for 
patients presenting with NSTEMI to primarily await delayed angiography and only seek 
emergent (<2 h) reperfusion therapy if deemed high-risk [5]. Approximately 30% of patients that 
fit NSTEMI criteria have unrecognized total occluded coronary arteries (TOCA) on delayed 
angiogram [6-7]. The delay in diagnosis and treatment results in increased morbidity, short-, and 
long-term mortality of patients. Furthermore, there is an increasing incidence of NSTEMI being 




recorded worldwide and in recent years approximately 70% of AMI patients are classified as 
NSTEMI [8-9]. However, STEMI criteria have a limited diagnostic accuracy, missing nearly 
one-third of ACO, and causing a substantial amount of false catherization laboratory activations 
[10]. In addition, our understanding of ECG changes indicative of ACO have expanded and 
include minor STE not fulfilling STEMI criteria, STE disproportionate to preceding QRS, 
unusual patterns with contiguous leads showing opposite ST deviations, and some patterns not 
showing STE at all. Attempts at integrating these other ECG findings indicative of ACO into 
terms such as “STEMI equivalents”, fail at gaining widespread understanding.  
For reasons outlined above, a gap in treating NSTEMI patients with ACO clearly exists, 
and thus a call for a paradigm shift to change the dichotomization of ACS into a more direct 
pathological understanding has been proposed. The proposed alternative paradigm to 
STEMI/NSTEMI is ACO-MI/non-ACO-MI or Occlusion Myocardial infarction (OMI) versus 
Non-Occlusion Myocardial Infarction (NOMI) for short. Simply put, do they present with 
occluded or near occluded coronary arteries with imminent myocardial damage requiring 
immediate intervention or not. By changing the paradigm to OMI/NOMI, diagnosis does not 
solely rely on ECG findings, which can be inconclusive, but includes clinical suspicion, ongoing 
symptoms, biomarker elevation, echocardiography, computed tomography, and conventional 
angiography. It is hypothesized that by transitioning to OMI/NOMI model for the evaluation of 
acute coronary syndrome in adult emergency department patients results in improved outcomes 
compared to the contemporary STEMI/NSTEMI paradigm. Objectives of this paper include 
outlining current ACS management, the limitations and historical development of 
STEMI/NSTEMI, and present the OMI/NOMI model and analyze how it compares.  
 





Current ACS Classification/Management  
When discussing suspicion for acute myocardial ischemia or infarction (AMI) an 
umbrella term of acute coronary syndromes (ACS) is traditionally utilized. Under the current 
classification system of ACS refers to one of three clinical syndromes: unstable angina (UA), 
non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation 
myocardial infarction (STEMI). The leading symptom in patients suspected of ACS is acute 
chest discomfort described as pain, pressure, tightness, and burning [5]. In addition, symptoms 
can include dyspnea, epigastric pain, and radiating pain. Suspected ACS patients ideally undergo 
a baseline resting ECG within 10 minutes of presentation two differentiate two types of patients 
with risk of myocardial infarction. Based on 12-lead ECG findings, patients are assigned to 
STEMI, if ST segment elevation is noted and are recommended to undergo immediate 
reperfusion by primary percutaneous coronary intervention (PCI) (door-to-balloon time within 
90 minutes), or fibrinolytic therapy if PCI is not available [11]. Patients with acute chest pain 
discomfort but no persistent ST elevated ECG are termed NSTEMI or UA, until positive serial 
cardiac markers rule in NSTEMI and rule out UA. NSTEMI patients are to undergo immediate 
invasive strategy (<2 hrs) only if deemed high-risk, which can be characterized by recurrent or 
ongoing chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and 
hemodynamic or electrical instability regardless of ECG or biomarker findings. Conventional 
teaching is that STEMI is generally regarded as reflecting an acute total or subtotal coronary 
occlusion completely interrupting blood supply and causing transmural ischemia. While 
NSTEMI is considered cardiomyocyte necrosis due to acute partial occlusion of a coronary 
vessel causing incomplete interruption of blood supply causing non-transmural (subendocardial) 




ischemia. However, it has been observed that totally occluded coronary arteries (TOCA) occurs 
among NSTEMI patients as well, and two recent meta-analyses reported approximately 30% of 
the patients diagnosed with NSTEMI had TOCA [7,12-13]. 
The diagnosis of AMI, (cardiomyocyte necrosis), in a clinical setting consistent with 
myocardial ischemia, is met when the following criteria are met; detection of an increase and/or 
decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin (hs-cTn) T or I, 
with at least one value above the 99th percentile of the upper reference limit and at least one of 
the following: 1. Symptoms of myocardial ischemia. 2. New ischemic ECG changes.  
3. Development of pathological Q waves on ECG. 4. Imaging evidence of loss of viable 
myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic 
etiology. 5. Intracoronary thrombus detected on angiography or autopsy [11].  
The increased access to high sensitivity troponin assays has led to an increased incidence 
rate of NSTEMI being recorded worldwide, as well as, nearly 70% of AMI patients being 
classified as NSTEMI in the United States [8-9].  Several definitions of AMI based upon 
assumed cause exist, the most common being Type 1 MI, which is characterized by 
atherosclerotic plaque disruption that results in intraluminal thrombus formation that impedes 
myocardial blood flow leading to myocardial necrosis. Type 2 MI is a consequence of mismatch 
between oxygen demand and oxygen supply that is caused by a condition other than plaque 
instability. Type 2 MI etiologies include hypotension, hypertension, tachyarrhythmias, 
bradyarrhythmias, anemia, hypoxemia, coronary artery spasm, spontaneous coronary artery 
dissection, coronary embolism, and coronary microvascular dysfunction. Most Type 1 and Type 
2 etiologies present as NSTEMI, however, can present as STEMI as well [14]. Type 3 MI 
involves patients with unexpected death before biomarkers are drawn or appear in the blood. 




Type 4 MI is associated with percutaneous coronary intervention (PCI). Finally, type 5 MI is 
from coronary artery bypass graft surgery (CABG).  
It is generally understood that invasive revascularization interventions are most useful in 
a Type 1 MI etiology. To maximize benefits of such interventions, deciding whether it should be 
done immediately/emergent (within 2 h), early (within 24 h), or delayed (within 25-72 h), and 
the selection of approach (PCI or coronary artery bypass grafting (CABG) need to be made as 
early as possible. Angiographic evidence is utilized to classify coronary artery patency using the 
TIMI Grade Flow scoring system. Grade 3 is normal flow with full perfusion, Grade 2 is delayed 
flow with full perfusion, Grade 1 is penetration without distal perfusion, Grade 0 is complete 
occlusion. It is the patients that have either a full occlusion, or near-occlusion with insufficient 
collateral circulation with imminent risk of irreversible infarction that benefit from emergent 
reperfusion therapy. Those whose myocardium is at risk, but not imminently, can be managed 
with medical therapy including antiplatelets, anticoagulants, and/or delayed reperfusion.  
Contemporary triage risk scores are utilized in identifying higher-risk patients that 
present with ACS to aid in risk stratification. The TIMI (Thrombolysis in Myocardial Infarction) 
score estimates adverse outcomes in patients with unstable angina or NSTEMI but can also be 
used to risk stratify patients with presumed ischemic chest pain. Similarly, the GRACE (Global 
Registry of Acute Coronary Events), estimates in-hospital, and 6-month to 3-year mortality in 
patients with known STEMI, unstable angina/NSTEMI to determine morality risk and guide 
more appropriate interventions. However, studies suggest neither TIMI risk score nor GRACE 
risk scores can very accurately identity which patients’ angina symptoms are due to ACS, and 
can only modestly identify NSTEMI patients with underlying TOCA who are at higher risk 
[7,13,15]. Guideline’s recommendation of delayed reperfusion in NSTEMI patients results in a 




mean time to angiography or PCI being more than 24 h [7,13]. Emergent reperfusion is 
recommended if NSTEMI patient is deemed high-risk, characterized by recurrent or ongoing 
chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and hemodynamic or 
electrical instability regardless of ECG or biomarker findings. There is also no difference in time 
to angiography or PCI between NSTEMI patients with or without TOCA [13].  
Historical Context of STEMI/NSTEMI Paradigm Development   
Before the reperfusion era ushered in the STEMI/NSTEMI paradigm, the first established 
MI paradigm was Q-wave/non-Q-wave MI dichotomy [16]. Retrospectively classifying patients 
based on Q wave development on ECG, or sign of irreversible transmural loss of myocardium, 
was the best available knowledge for the better part of the 20th century. The historical timeline of 
major events providing insights into the pathogenesis and management of AMI leading up to the 
reperfusion era is presented Fig. 1 [17]. The 1980s and early 1990s were defined by landmark 
trials and meta-analyses showing IV fibrinolytics had substantial survival benefits and outcomes 
for suspected ACS patients, especially when given early [2,18,19].   
The randomized control studies evaluating fibrinolytics use in patients presenting with 
AMI began to shift our paradigm from retrospective diagnosis and seldom treatment options, but 
rather towards prospective identification and treatment. The 1994 Fibrinolytic Therapy Trialists’ 
(FTT) meta-analysis pooled data from 58,600 patients enrolled in 9 randomized control studies 
using highly suspicious patients presenting with acute chest pain that were randomized to either 
thrombolytics or placebo [2]. The average number of patients needed to treat to benefit one of 
the patients expressed as NNT, was 56 from lytics compared to placebo, showing a significant 
mortality benefit before performing any subgroup analysis. Subset analysis of the groups from 
the RCTs was done to determine which groups had the highest benefit or harms. The subgroups 




were defined vaguely by ECG findings of “ST elevation (STE)”, “ST depression (STD)”, or 
“Normal”. Only five of the RCTs had defined their version of STE, which had varying cutoffs 
and methods of measurement. The definition of “Normal” and “STD” were not adequately 
defined either. The remaining four of the nine trials did not use ECG for enrollment. Upon subset 
analysis, STE was found to be the most closely associated ECG finding as an arbiter of 
fibrinolytic administration which improved NNT for short term mortality from 56 to 43. On the 
other hand, those subset groups defined as “Normal” or “STD” showed a non-significant trend 
towards mortality harm expressed as number needed to harm (NNH), (NNH=143, 42). The meta-
analysis helped identify that the poorly defined “STE” can be used as surrogate marker to predict 
potential acute coronary occlusion (ACO) and thus mortality benefit from lytics than not looking 
at the ECG at all. The meta-analysis did not use angiographic findings to identify which patients 
had an ACO. In 2000, the ACC/AHA guidelines formally changed the paradigm from Q-wave 
vs. non-Q wave MI to STEMI vs NSTEMI [20].  
Research continued focusing on delineating what appropriate amount of STE was 
deemed a STEMI and fine tuning it, but often failing to utilize angiographic evidence to 
determine who indeed had an ACO. Menown et al., utilized ECG and biomarker findings using 
1,190 subjects to determine that ≥ 2 STE in at least one of the anteroseptal leads, or ≥1mm in any 
of the other leads which had a 56% sensitivity and 94% specificity for AMI vs no AMI [3]. The 
study did correctly classify 83% of patients as having AMI, however not utilizing angiography 
means patients without occlusion were included. The results suggest the approach can predict 
AMI accurately, but the same cannot hold true for predicting ACO. The result of the study 
instituted the First Universal Definition of MI and the first STEMI criteria findings: patients with 
STE that had new or presumed new ST segment elevation in two or more contiguous leads with 




≥0.2 mV in leads V1, V2, or V3, or ≥0.1 mV in other leads. Patients without STE could have 
findings indicative of ischemia that could progress to MI were STD, or T-wave abnormalities 
that should be observed in two or more contiguous leads, or symmetric inversion of T waves 
≥1mm in at least two contiguous leads [21]. Subsequent studies by Mcfarlane et al. and Wu et 
al., found that ironically baseline STE was a common appearance among apparently healthy 
adults who presumably did not have ACO [4,22]. Wu et al. even found that 2% of Chinese males 
aged 18-40 had 3mm or more of J point elevation in V1 and V2 at baseline, which is at odds of 
the first universal definition of MI [22]. Regardless, in 2004 the ACC/AHA recommended that 
STE of ≥1mm in any two contiguous leads or adjacent limb leads warranted fibrinolytic therapy 
with symptom onset within the prior 12 hours [23].  
The Second Universal Definition of MI came about in 2007 after research showed that 
implementing sex-based cutoffs for STEMI criteria would increase the sensitivity and specificity 
of correlating ECG findings to elevated biomarkers [24-25]. The Second Universal Definition 
recommended two contiguous leads with at least 1.0mm STE, except for leads V2-V3 which 
requires 1.5mm in women and 2.0mm in men [25]. The definition was primarily based on what 
Macfarlane et al. had found performing a logistic regression technique to revise the STEMI 
criteria based on age and sex-based cutoffs, which increased sensitivity from 42% to 47% and 
specificity from 96% to 99% when correlating the ECG findings to biomarker elevation [24]. No 
angiographic evidence was utilized, so data on ACO patients was not reported.   
In 2009, the current STEMI criteria were introduced with both age and sex-based cutoffs 
for STE being, new ST-elevation at the J-point in 2 contiguous leads with the cut-point: ≥1 mm 
in all leads other than leads V2–V3 where the following cut-points apply: ≥2 mm in men ≥40 
years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age [26]. For STD and T-




wave changes new horizontal or downsloping ST-depression ≥0.5 mm in 2 contiguous leads 
and/or T inversion >1 mm in two contiguous leads with prominent R wave or R/S ratio >1 were 
defined. These criteria were subsequently included into the 2012 development of the Third 
Universal Definition of MI, with the addition of some minor reference that other ECG findings 
like hyperacute T-waves can possibly represent AMI [27]. The ST-elevation criteria have 
continued to be included in even the most recent 2018 fourth universal definition of MI [28]. 
STEMI criteria has become the guideline-based approach to diagnosing ACO with a notion that 
it is the most accurate marker for determining ACO, and thus a marker for who needs emergent 
reperfusion therapy.  
STEMI/NSTEMI Paradigm is Inaccurate and Detrimental  
Just as Q-wave/non-Q wave served as a surrogate ECG marker for MI previously, 
STEMI/NSTEMI is currently serving that identical purpose as a marker of acute coronary 
occlusion that fails to account for the underlying pathology. Keeping the underlying pathology in 
mind, STEMI criteria fails to identify acute coronary occlusion accurately.  
Schmitt et al. was one of the first to find the limitations of utilizing STEMI criteria [29]. 
A total of 1,788 patients with suspected AMI based on clinical symptoms and positive CK-MB, 
were prospectively enrolled for emergent coronary angiography. In total 23% had confirmed 
ACO (418/1788), and out of those 418 patients, 29% did not meet STEMI criteria. The least 
sensitive measure of STEMI criteria was in those presenting with an acute left circumflex 
occlusion which had a high miss rate of 50%. The PARAGON-B trial was a randomized control 
study using 1,957 patients with non-STE ACS presentation [30]. It was found that 27% of those 
patients had completely occluded culprit vessels on next day angiography. In addition, it was 
found that these patients had larger infarcts (median peak creatine kinase–MB 4.3 vs 2.1 × upper 




limit of normal, P < .0001) and higher risk adjusted 6-month mortality (hazard ratio 1.72, 95% 
CI 1.07-2.79) despite similar in hospital treatment. Similar findings were found in the TRITON-
TIMI-38 randomized control trial for patients undergoing cardiac catherization, in which 26.2% 
had completely occluded culprit arteries at the time of catherization [31]. Additionally, 48.4% of 
those with occlusion, the culprit artery was the left circumflex. The 30-day incidence of 
composite of death and MI was significantly higher in the occluded artery group and the median 
time from ECG to PCI was 29.4 hours. Khan et al., performed a meta-analysis from seven 
studies in which NSTEMI patients were prospectively enrolled and assessed for occluded culprit 
arteries [32]. Out of 40,777 NSTEMI patients, 10,415 (25.5%) had total occluded coronary 
arteries (TOCA) found on angiography an average of 24 hours after presentation. Furthermore, 
these unrecognized ACO patients had increased risk of both MACE (major adverse 
cardiovascular events) in the short and medium to long term, and all-cause mortality.  
Overall, NSTEMI patients with unrecognized ACO face adverse cardiovascular events. 
Even the most recent publications show that NSTEMI with ACO compared to NSTEMI without 
ACO have increased mortality ratios, increased re-infarction rates, and increased mortality in the 
short and long term [7,13]. The authors concluded better risk stratification tools are needed to 
facilitate earlier revascularization and improving outcomes in NSTEMI patients with ACO, 
because of the increased risks associated with missing the diagnosis [13].  
Studies highlight a substantial amount of ACO patients present with subtle STE not 
fulfilling current STEMI criteria. One study found that patients with angiographic evident ACO 
presenting with subtle STE of (.1-1mm), 18.3% had not even a single lead with 1mm STE [33]. 
Despite having smaller infarcts, the subtle STE subgroup had more frequent multivessel disease, 
larger delays to reperfusion, and was not associated with better outcomes. Smith et al., 




retrospectively compared 143 subtle proven acute left anterior descending (LAD) occlusions and 
found that 22% of patients (33) that had subtle LAD occlusion with a mean STE ≤1mm, 19 
patients with no leads showing more than 1mm, and 8 patients with less than or equal to 1mm in 
only 1 lead [34]. AM et al., analyzed 1,500 consecutive patients with angiographic complete or 
near occlusion to determine if through re-reading their ECG they would meet STEMI criteria 
[35]. Surprisingly, even with the bias of knowing these patients had ACO in addition to using a 
more liberal cutoff of ≥ 1mm STE in any 2 contiguous leads, 28% (423) patients still did not 
meet the criteria.  
Another failure of utilizing STEMI ECG criteria is that it has poor accuracy among 
clinicians and has poor interrater reliability for detecting ACO. McCabe et al., performed a cross 
sectional survey using EM physicians and cardiologists to review 36 ECG for prospective 
STEMI activation [36]. 24 of the ECGs were true positives (STEMI), while 12 of the cases had 
no culprit lesion (no STEMI). Physicians were asked “based on the ECG above, is there a 
blocked coronary artery present causing a STEMI?”. 124 physicians interpreted a total of 4,392 
ECGs and showed that intrareader agreement (kappa) for ECG interpretation was 0.33, reflecting 
poor agreement. Sensitivity to identify true STEMIs was 65% and specificity was 79% [36]. 
Interesting enough, even after adjusting for experience there was no difference in the odds of 
overall accurate interpretation between specialties [36]. Other studies have also showed poor 
interrater reliability and wide variations among experienced electrocardiographs in determining 
which ECGs had STE with need for PCI from nonischemic STE [37-38]. Carley et al. showed 
that even among physicians that commonly prescribe thrombolysis the observed STE magnitude 
varied, because doctors use a wide variety of points on the ST segment to assess elevation [39]. 




Most recently prospective cardiologist subjective evaluation revealed only 49% sensitivity for 
predicting ACO [40].  
In addition to failing to identify ACO, STEMI criteria leads to many false STEMI 
activations. In one study out of 411 STEMI activations by EM physicians, 146 (36%) were 
deemed false positive that did not warrant PCI [41]. In another study using 1,335 patients from 
31 regional hospitals in Minnesota who presented with suspected STEMI and underwent 
angiography, 187 (14%) did not have a clear culprit coronary artery, 9.5% did not have 
significant coronary artery disease, and 11.2% had negative biomarkers [42].  
 The development of computerized diagnostic algorithms to assist in the interpretation of 
ECG has been used in suggesting STEMI, but the research shows that even automated 
interpretation has high rates of error [43-45]. The algorithms have a wide variation of false 
positives (0-42%), and false negative results (22-24%). Hillinger et al., in a prospective 
validation of current ECG criteria reported recently that sensitivity of computer algorithm 
measurement was 21%, and for cardiologist-adjudicated STEMI was still remarkably low (35%) 
[40]. The recommendation is that computer-assisted ECG interpretation should not be used as a 
sole means to diagnose STEMI, but it still can bias physician judgement [46-47]. Furthermore, 
computer interpretation basis is on STEMI criteria and can miss the subtle ST elevation, (which 
may be significant in small amplitude QRS complexes), ST depression in aVL (which is 
sensitive for inferior MI), and subtle signs of LAD occlusion like terminal QRS distortion [48]. 
Finally, if the computer interpretation reads “normal” it must be carefully interpreted because it 
can miss the ischemic morphology (straight or convex ST segments, terminal T wave inversion, 
down-up T waves, hyperacute T waves, and inverted U waves), and dynamic changes (subtle 
changes, pseudonormalization of ST segments, or T-waves) [48-49]. 




STEMI Paradigm Misses Other Findings  
The final point towards why STEMI/NSTEMI fails as a paradigm for ACO is that it acts 
as a cognitive roadblock. The words STEMI make one cognitively assume that STE is the only 
ECG variable that matters, missing other subtleties of ECG interpretation [50]. For example, 
proportionality of STE, STD, or T-wave size must be assessed relative to the QRS amplitude, 
which is absent from STEMI/NSTEMI criteria [51]. With lower QRS voltage, the more 
significant any STE/STD/T-wave size becomes. 
Rules for determining subtle left anterior descending (LAD) coronary occlusion over 
normal variant STE have been found to be very accurate utilizing a four variable formula 
resulting in sensitivity of 86% and specificity of 92% for LAD occlusion [52]. Normal variant 
STE is also shown to present with an S-wave or a prominent J-wave notch in both V2 and V3, 
and absence of it is termed “terminal QRS distortion” seen only in LAD-ACO with a 100% 
specificity [53]. In subtle inferior STE, looking at aVL, which is the only lead that is truly 
opponent the inferior wall, and finding evidence of any STD is a sensitive, early sign of inferior 
ACO [54-55]. 
STE due to secondary repolarization abnormalities have also been evaluated for more 
diagnostic ECG findings of ACO. For example, modified Sgarbossa criteria have been evaluated 
to accurately diagnose ACO in presence of left bundle branch block (LBBB) (sensitivity=91%, 
specificity 90%), or ventricular paced rhythm (sensitivity=67%, specificity 99%) [56-57]. It has 
been shown that STE >25% of the QRS amplitude can specifically be used for differentiating 
STE due to ACO from STE due to left ventricular hypertrophy with sensitivity 64%, specificity 
93% [58]. Rules for differentiating STE from post-MI ventricular aneurysm or pericarditis from 
ACO have also been published with high sensitivity (91%, 98%) and specificity (81%, 100%) 




[59-60]. Shaikh et al., has recently proposed ACS patience presenting with new onset right 
bundle branch block (RBBB) to potentially be a “STEMI equivalent” finding to indicate acute 
reperfusion, because of it likely indicating proximal occlusion of the LAD [61]. 
Notable patterns without contiguous STE can also indicate ACO. Aslanger’s pattern may 
present in about 6.3% of NSTEMI patients and represent approximately 13.3% of inferior ACO, 
often revealing multivessel disease and resulting in higher mortality risks [62]. Another example 
of a noncontiguous STE pattern is the recently published South African flag sign, indicative of a 
diagonal occlusion [63]. Isolated posterior MI is commonly missed due to it not presenting on 
standard 12 lead ECG with STE, but rather reciprocal changes are seen on anteroseptal leads 
with STD, which might require additional V7-V9 leads placed on the posterior chest to 
adequately detect [31] 
Dynamic ECG findings not showing any ST deviation can also indicate ACO. 
Hyperacute T-waves, widely considered a precursor sign of ACO and preceding evolvement to a 
STEMI pattern, is described as broad-based, asymmetrical, and tall compared with preceding R-
wave, most apparent with ACO of the LAD [64]. In addition, de Winter pattern, widely 
considered a “STEMI equivalent”, in part due to its high positive predictive value of ACO, is a 
form of hyperacute T-wave with ST depression [65]. Wellens syndrome presents as an ECG 
pattern primarily showing biphasic or deeply inverted T-waves in leads V2-V3 requiring early 
recognition as it represents a pre-infarction state of the LAD, with previous reports of 75% of 
patients developing infarction without definitive PCI intervention [66].  Shark fin appearance 
caused by fusion of QRS, ST-segment, and T waves, is another high-risk pattern reflecting 
presence of large area of transmural ischemia and predicting significant mortality [67]. 
Furthermore, serial ECGs obtained over 15-30 minute intervals over the first hour might be 




required to capture some of the dynamic changes that occur in an AMI, and has been shown to 
improve the sensitivity for STEMI and ACS [68]. Other high-risk criteria potentially indicating 
ACO include (transient STE, poor QRS voltage, resting U wave inversions, multiple leads 
showing STD and/or significant magnitudes of STD, etc..) summarized in Table 1 [51]. Images 
of ECG signs by suspected culprit coronary artery are presented in the appendix (Fig. 2-Fig. 5) 
[51].  
ECGs can be inconclusive and utilization of clinical, laboratory, and imaging 
characteristics to identify high risk NSTEMI patients with ACO can aid in timely definitive 
treatment. Utilizing data from 17,739 NSTEMI patients with totally occluded coronary arteries 
revealed approximately 70% were male and a majority were between 58-69 years old [7,13]. 
Risk factors like hypertension, diabetes mellitus, dyslipidemia, and smoking use were also 
associated with increased occlusion in NSTEMI patients. Characteristics of chest pain such as 
severity, duration, number of episodes, and persistence despite medical treatment raise suspicion 
for ACO as well.  
Echocardiograph findings can also aid in determining high risk NSTEMI patients, since 
changes can present prior to ECG changes or development of symptoms [69]. Regional wall 
motion abnormalities on echocardiography localize to territories of occluded coronary arteries 
and can be visualized by abnormalities in segmental motion described as hypokinetic, akinetic, 
or dyskinetic. Reduced left ventricular ejection fraction, new or worsening mitral regurgitation, 
and new ventricular septal defects have been recognized as markers of risk severity in NSTEMI 
patients [5,70]. Determining myocardial strain through speckle-tracking echocardiography has 
also been used to identify ACO with high accuracy when territorial circumferential strain value 
was >-10% [71].  




Other imaging modalities for NSTEMI patients with possible occlusions include 
computed tomography (CT) coronary angiography. Results from the follow up study of the 
VERDICT trial showed CT coronary angiography to be equivalent to invasive coronary 
angiography in differentiating obstructive and nonobstructive coronary artery disease, thus being 
a potential timely non-invasive approach to aid in definitive diagnosis [72].  
OMI/NOMI Paradigm  
 A classification system other than STEMI/NSTEMI for ACS has been proposed [73] An 
accurate proposal is one that considers the pathophysiologic substrate, which would be an acute 
coronary occlusion MI vs non-acute coronary occlusion MI, or to put it shortly occluded MI vs 
non-occluded MI (OMI vs NOMI). OMI conceptually equating to an acute coronary occlusion or 
near occlusion with insufficient collateral circulation, such that downstream myocardium will 
undergo imminent infarction without emergent reperfusion. NOMI refers to an AMI without 
angiographic, laboratory, or clinical evidence of OMI, or using the current paradigm, an 
NSTEMI without occlusion. Utilizing the OMI/NOMI framework does not only limit to ECG 
interpretations, which can sometimes be nondiagnostic, but also includes diagnosis via 
biomarkers, echocardiography, computed tomography, and/or conventional angiography [50].  
Definitions that come about with introducing the new paradigm whilst including the 
current guidelines are as follows. STEMI (+) OMI is a true positive STEMI, which means it 
meets current STEMI criteria and is found to have OMI as the cause of the STE and AMI. 
STEMI (-) OMI refers to patients that do not meet ECG STEMI criteria but have an occlusion 
(an NSTEMI with occlusion). False positive STEMI refers to those meeting STEMI criteria, but 
the STE is not due to ischemia and there is absence of OMI on angiogram. The ACS spectrum 




using primarily STEMI/NSTEMI paradigm and OMI/NOMI paradigm are displayed in the 
appendix (Fig. 6, Fig. 7) [74].  
Meyers et al., retrospectively reviewed 467 high-risk ACS patients and directly compared 
STEMI/NSTEMI with the OMI/NOMI paradigm [74]. OMI was defined as an acute culprit and 
either TIMI 0-2 flow or TIMI 3 flow plus peak troponin T > 1.0 ng/mL. Out of the 467 high-risk 
ACS patients 234 had an AMI (50.1%). In total 108 met OMI criteria with 67 being STEMI (+) 
(62%) and 41 being STEMI (-) (38%). Median peak troponin T between STEMI (+) OMI was 
similar to STEMI (-) OMI (5.36ng/mL vs. 4.44ng/mL). Rates of new or presumed new wall 
motion abnormalities was similar as well (86% vs. 75%). A composite outcome of 
catheterization cardiac arrest, in-hospital mortality, or survival with discharge to hospice was 
18% and 15% between STEMI (+) OMI and STEMI (-) OMI. Median time from arrival to cath 
was delayed in STEMI (-) OMI patients (437 vs. 41 minutes), with only 28% undergoing cath in 
less than 90 minutes compared to 76% in the STEMI (+) OMI group (p<0.001).   
Meyers et al., recently performed a retrospective case control study of 808 patients with 
suspected ACS symptoms and compared structured expert ECG interpretation suggestive of OMI 
to STEMI criteria for the diagnosis of an OMI [75]. OMI was defined as either an acute culprit 
artery with TIMI flow of 0-2, or a culprit artery with TIMI flow 3 with peak troponin 
T ≥1.0 ng/mL or I ≥10.0 ng/mL. The expert ECG findings considered these 8 other findings 
highly suggestive of OMI, “subtle STE not meeting criteria, hyperacute T waves (including de 
Winter pattern), reciprocal ST depression and/or negative hyperacute T waves, STD maximal in 
V1-V4 indicative of posterior OMI, suspected acute pathologic Q waves (meaning Q waves 
associated with subtle STE which cannot be attributed to old MI), terminal QRS distortion 
(absence of S-wave preceding any subtle STE, where an S-wave would be expected), any STE in 




inferior leads with any STD or T wave inversion in lead aVL, and positive modified Sgarbossa 
criteria (MSC) for a patient with left bundle branch block (LBBB) or ventricular paced rhythm 
(VPR)” . In total 49% had an AMI with 265 (33%) having an OMI, and only 41% of total OMI 
patients meeting STEMI criteria. The results showed higher sensitivity, and similar specificity 
using OMI criteria compared to STEMI criteria among the two interpreters (Interpreter 1 
sensitivity 86% vs 41%, specificity 91% vs 94%), (Interpreter 2 sensitivity 80% vs 36%, 
specificity 92% vs 91%). Inter-rater reliability was high between interpreters with a 97.2% 
(kappa value of 0.893) for determining STEMI criteria and 94% agreement for the diagnosis of 
OMI (kappa value of .849). OMI criteria lead to correctly identifying 146 (55%) of OMI patients 
an average of 3 hours and median of 1.5 hours earlier than using STEMI criteria. Out of the 146 
patients with OMI, 120 never met STEMI criteria on any serial ECG recordings. Most common 
OMI ECG findings were subtle STE not meeting STEMI criteria (83%) and reciprocal ST 
depression and/or reciprocal T-wave inversion (82%). The STEMI (-) OMI patients had similar 
infarct sizes as STEMI (+) OMI patients (average peak TnT ng/mL 5.29 vs 6.06) but had greater 
delays to angiography with average time to cath (1,181 minutes vs. 265 minutes) and less 
undergoing cath <90 minutes from presentation (38% vs. 71%).  
The DIFOCCULT study also compared the OMI/NOMI approach versus 
STEMI/NSTEMI and was the largest designed study to date challenging the current paradigm 
[10]. It was a single center, retrospective case control study of adult patients presenting to the 
emergency department clinically for ACS at a tertiary care center for PCI in Turkey. Utilizing 
the fourth universal definition of MI, the three groups were STEMI, NSTEMI, Control (ACS 
excluded). ACO was defined by total occlusion or presence of culprit lesion on angiography with 
peak troponins I level equal to or greater than 1.0ng/ml + an at least 20% rise within 24 hours, a 




highly elevated peak troponin (greater than 5.0 ng/ml), or cardiac arrest before any troponin rise 
has been documented with supporting clinical evidence of possible ACO. The study ruled out 
15,510 ACS patients by serial troponin, and had 1,152 patients with STEMI, 2,352 with 
NSTEMI. Using 1,000 patients for each group analysis, those initially classified as having 
NSTEMI, 282 (28.2%) were re-classified by ECG reviewers as having OMI due to minor STE 
with reciprocal STD (215), hyperacute T waves or de Winter’s patterns (35), subtle anterior STE 
(18), nonconsecutive STE (14). Inter-observer agreement was high for detecting these subtle 
ECGs (kappa=0.834). Reclassified NSTEMI had a frequency of ACO of 60.9%, while the 
frequency of ACO in STEMI was 85.3%. Myocardial damage by 24 to 48 hour troponin I 
measure showed reclassified NSTEMI had (5.703ng/ml), STEMI: (32.990 ng/ml), non-
reclassified NSTEMI: (0.622ng/ml). Mortality rates were similar between reclassified NSTEMI 
and STEMI in hospital (5.0% vs. 8.3%), and long-term (10.6% vs. 13.7%).  In terms of 
diagnostic accuracy for ACO after weighted values corrected for real admission rates of each 
group the OMI/NOMI approach was overall superior to STEMI/NSTEMI with sensitivity 
(67.9% vs. 54.4%), specificity (96.7% vs. 99.0%), positive predictive value (68.2 vs. 43.4), and 
negative predictive value (96.6 vs. 94.9). In addition, accuracy for long term mortality weighted 
was also shown to be overall higher using the OMI/NOMI approach compared to 
STEMI/NSTEMI with sensitivity (64.6% vs. 50.4%), specificity (91.4% vs. 88.8%), positive 
predictive value (11.4 vs. 7.1), and negative predictive value (99.3 vs. 99.1). In this study, 17.9% 
of ACO in the NSTEMI group were still missed.  
 Implementing teaching of more subtle ECG findings included under the OMI/NOMI 
paradigm has been successfully done and has even lead to outcome improvement. A recent 
multi-centre quality improvement initiative to educate emergency physicians on OMI ECG 




findings was done to reduce diagnostic time for patients presenting with ACO [48]. First 
emergency department ECG to the time a Code STEMI was activated, or ECG-to-Activation 
(ETA) time, was measured to reflect emergency physician clinical decision making. Also, 
percentage of Code STEMIs without culprit lesions was measured. Education was primarily 
done through weekly web-based feedback on unnecessary cath lab activations and on STEMI-
equivalents/subtle occlusion findings. ETA time was reduced by 20 minutes, from 28.0 (95% 
confidence interval [CI] 15.0–45.0) to 8.0 (95% CI 6.0–15.0), which is clinically significant, and 
was done without increasing the percentage of Code STEMIs without culprit lesions; baseline of 
28.2% (95% confidence interval [CI] 17.8 to 38.6) and interventional period 20.0% (95% CI 
11.2 to 28.8). The most common improvement in ECG diagnosis of ACO was subtle LAD 
occlusion (e.g. borderline anterior ST elevation with convex ST segments, hyperacute T waves 
or reciprocal changes), subtle inferior MI (minor inferior ST elevation with reciprocal ST 


















Literature review was first conducted utilizing Dr. Smith’s ECG Blog, under which OMI 
relevant literature is compiled. Meyers and Smith’s “OMI Manifesto” served as the initial 
principal source for journal articles relevant to STEMI/NSTEMI and OMI/NOMI literature. 
Independent review of the cited literature was performed. Personal analysis of original studies 
allowed for deeper understanding and verification of material accuracy. In addition, literature 
searches were conducted primarily using PubMed literature database and Google Scholar. 
Keywords for searches included “ACS”, “STEMI vs NSTEMI”, “STEMI”, “NSTEMI”, ”OMI vs 
NOMI”, “OMI”, “NOMI” were performed. Articles that were relevant to the thesis topic were 
reviewed and included. Searches were limited to articles in which access to full texts could be 
obtained. The Augsburg University’s Lindell Library interlibrary loan was utilized to obtain 
some articles. Figures and tables from several articles that were found useful were included in 






















The objective of this paper was to conduct an evaluation of the current AMI paradigm 
STEMI/NSTEMI and compare it to the newly emerging paradigm OMI/NOMI for evaluation of 
patients presenting with ACS to determine whether a new paradigm would result in better 
outcomes. Although the research is still limited, there are several findings that ultimately point 
towards the benefits of using the OMI/NOMI paradigm.  
Shortfalls of STEMI/NSTEMI 
When examining the historical development of STEMI/NSTEMI criteria to diagnose 
ACO there is clearly poor methodology that has led to the adoption of it into current guidelines. 
Ushering in the era of reperfusion therapy in part due to placebo-controlled trials utilizing 
thrombolytics, without subset analysis, showed that patients benefited when presenting with 
symptoms associated with ACS. ECGs were used to further analyze who would benefit the most 
from lytics, however, in the meta-analyses the definitions of “STE”, “STD”, and “normal” were 
poorly defined and varied substantially between the RCTs [2]. In addition to poorly defined 
metrics, the lack of angiography evidence of ACO in the studies did not prove if in fact STE 
patients, who were shown to have decreased mortality with thrombolytics, had pathology 
warranting emergent reperfusion. The results do suggest that overall, the STE subgroup likely 
had more ACO patients, thus benefiting more from thrombolytics, but still neglects false 
positives in the group and false negatives in the non-STE group. The studies showing 
thrombolytics are beneficial in AMI patients should have been taken as mere beginning to risk 
stratifying ACO patients, but instead led to STEMI being synonymous with ACO requiring 
emergent reperfusion therapy. Research refining STE criteria was also done without proper 
methodology incorporating angiographic evidence of occlusions, but rather dependent on 




biomarker positivity, which lacks sensitivity for ACO. Evaluating the historical research 
revealed that AMI diagnosed by biomarkers is the outcome that was utilized to determine ECG 
findings and fine tune STEMI criteria, disregarding any other potential ECG findings of ACO in 
the process. Using angiographic evidence to correlate with ECG findings would have been a 
better approach in assessing patients presenting with ACO, because then determining who would 
benefit most from emergent reperfusion therapy could be made.   
When examining the accuracy of STEMI/NSTEMI for discovering ACO, the evidence 
shows that it misses approximately 25-30% of ACO in NSTEMI presenting patients, and 
sometimes even as high as 50% in ECG silent coronary arteries like the Left circumflex [6, 29]. 
STEMI criteria results in almost 14-36% of false cath lab activations in patients that are found to 
not have culprit lesions [41-42]. With patients that undergo false positive activation the risks 
outweigh the benefits, with possible exposure to complications of coronary angiography 
including coronary dissections, perforations, early diagnostic closure, arterial punctures, contrast 
associated nephropathy, bleeding complications, and large costs. The accuracy of interpretation 
by both computer algorithm identification and amongst expert clinicians, including cardiologists, 
shows that it has low specificity and sensitivity to be useful in diagnosing ACO [40]. In addition, 
reliance on computer interpretation can miss many dynamic changes and other morphologies 
indicative of ACO, yet clinicians often find readings of “Normal” as a reassuring sign. It is often 
on next day angiography that NSTEMI patients with ACO are discovered, which leads to almost 
double short- and long-term mortality compared to NSTEMI patients without occlusion [13]. It is 
clear that the STEMI/NSTEMI paradigm is inaccurate in diagnosing ACO, and detrimental to the 
NSTEMI patients with ACO that are routinely missed.  




As a cognitive roadblock the STEMI/NSTEMI paradigm continues to undermine 
progress in several ways. It presents itself in a way that makes one think that STE on ECG is the 
most important marker of ACO, disregarding any other potential ECG findings that investigators 
have found to be indicative of ACO with high accuracy [51]. Furthermore, when the ECG is non-
diagnostic, focus on other clinical, laboratory, and imaging findings can be valuable in 
determining high risk individuals needing emergent reperfusion, but current guidelines simply 
fail to emphasize the use of them [51,72]. Classifying patients based on a surrogate marker, 
which STEMI/NSTEMI does, misses the underlying pathology of acute coronary occlusion, and 
misses the bigger picture of what needs to be determined clinically; who needs emergent 
reperfusion therapy and who does not? Improvements via retrospective analysis to improve ACO 
discovery is also rather difficult under the current paradigm since we are taught lack of STE is a 
reassuring sign, disregard the harms in missing STEMI (-) OMI patients, and group NSTEMI 
patients as one homogenous group even when ACO is discovered later in the clinical course.  
OMI/NOMI as a Better Paradigm  
To improve outcomes in patients with ACO the underlying pathology must be the center 
of a paradigm. OMI/NOMI is an emerging paradigm that can do that, by OMI conceptually 
equating to as an acute coronary occlusion or near occlusion with insufficient collateral 
circulation, such that downstream myocardium will undergo imminent infarction without timely 
reperfusion. OMI emphasizes the underlying pathology and so in return utilizes all diagnostic 
factors including many other ECG findings, biomarkers, echocardiography, computed 
tomography, or conventional angiography [51].   
It has been shown that the OMI/NOMI approach using other ECG findings indicative of 
ACO compared to STEMI/NSTEMI criteria results in more accurate diagnosis of ACO [74-75]. 




Comparing STEMI (-) OMI patients to STEMI (+) OMI patients shows similar infarct sizes and 
mortality risks, yet delayed time to angiography. With the OMI/NOMI approach earlier 
diagnosis of ACO was achieved in 55% of the OMI cohort on average 3 hours earlier and a 
median of 1.5 hours than using the STEMI/NSTEMI model [75]. It is also evident that ECG 
interpretation can be improved upon through educational feedback programs for emergency 
physicians, which has shown to decrease cath lab activation time with more accurate 
interventions [48]. Taking the current literature together suggests that ultimately using the 
OMI/NOMI model leads to a more accurate and timely diagnosis in patients presenting with 
potential ACO, leading to earlier definitive intervention and thus improved mortality and 
morbidity outcomes.  
Limitations  
Limitations of the research on OMI/NOMI compared to STEMI/NSTEMI exist. The 
research directly comparing the two paradigms were primarily retrospective which can create 
bias, external validity issues, and long term follow up data difficult to generalize. One of the 
bigger limitations is that a randomized clinical trial of immediate vs. delayed angiography is 
needed to determine if STEMI (-) OMI patients would indeed undergo earlier intervention than 
STEMI (+) OMI patients and have improved outcomes. With OMI/NOMI paradigm and 
proposed algorithm still showed 17.9% of ACO is missed [10]. However, by moving to a 
paradigm that is more open to discovering new ECG findings and utilizing other factors 
indicative of ACO, that number will likely go down. ECG interpretation is subjective and 
requires experience for accurate interpretation. The subtleties and complexities associated with 
the other ECG findings suggestive of ACO will likely make the OMI/NOMI approach more 
difficult to novice interpreters. Furthermore, ECG findings need to be interpreted in the clinical 




context as well. But it has also been shown that clinicians can adapt and broaden their ECG 
understanding to improve diagnosis ability [48]. By instituting the OMI/NOMI paradigm 
potentially new trials can be performed, the research can be furthered, and ultimately patients can 
benefit in the long run. Indeed, future results are always contingent on parameters outside merely 
diagnosing ACO, and improvements in factors such as revascularization procedures and post 
cardiac rehabilitation will be vital in treating patients and improving outcomes as well. 
Conclusion:  
ACS continues to be a significant proportion of patients presenting to emergency 
department, yet our current dichotomous STEMI/NSTEMI paradigm fails to adequately capture 
all of the patients requiring emergent reperfusion therapy. Examining the historical context in 
which STEMI/NSTEMI was developed reveals flawed methodology that has nevertheless led to 
it becoming the dogmatic approach to determining who has ACO requiring emergent reperfusion 
therapy. Furthermore, as a paradigm it fails to progress the knowledge of ACO and hinders a 
substantial amount of ACS patients from receiving definitive treatment. With nearly 30% of 
NSTEMI patients having totally occluded coronary arteries determined on delayed angiography 
the need for a paradigm shift to capture these patients is required to improve outcomes. Focusing 
on an ECG surrogate marker of ACO fails to consider the underlying pathophysiology. The 
OMI/NOMI paradigm is more inclusive of other ECG findings shown to be highly accurate 
indicators of ACO, as well as use of echocardiography, biomarkers, computed tomography, and 
conventional angiography. When the OMI/NOMI paradigm approach of ECG interpretation was 
compared to STEMI/NSTEMI, earlier and more accurate diagnosis was made. Furthermore, 
when other ACO indicative ECG findings under the OMI/NOMI model were taught to 
emergency physicians, cath lab activation was faster and more accurate supporting its usefulness 




as a model. The findings presented in this paper suggest the OMI/NOMI paradigm can 
successfully improve outcomes in patients presenting to the ED with ACS, but future 
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Figure 1. A timeline of major events providing insights into the acute myocardial infarction 




















Table 1. Electrocardiographic signs indicative of non-ST elevation myocardial 
infarction with total occlusion of the culprit coronary artery [51]. 
Non-coronary specific signs 
 Total number of leads showing ST-segment depression (>3) 
 Total ST-segment depression sum (≥ 6 mm) 
 ST-segment depression > 2 mm in any lead 
 Presence of q waves in ≥ 2 contiguous leads 
 Hyperacute T waves 
 ‘Shark-fin’ – triangular waveform ECG pattern 
 Transient ST-segment elevation 
 Low QRS voltage 
LAD specific signs 
 Hyperacute T waves 
 De Winter's sign 
 Wellens' sign (Type A & Type B) 
 ‘Shark-fin’ – triangular waveform ECG pattern 
 New RBBB 
 Resting U-wave inversion 
LCx specific signs 
 ST-segment depression and/or T-wave inversion in inferolateral leads 
 ST-segment depression in V1-V3 leads 
 ST-segment elevation in V7-V8 leads 
 Prominent R-waves in V1-V2 (R/S > 1) with upright T waves V1-V3 
RCA specific signs 
 ST-segment depression and/or T-wave inversion in inferolateral leads 
 ST-segment depression in V1-V3 leads 
 ST-segment elevation in V7-V8 leads 
 Prominent R-waves in V1-V2 (R/S > 1) with upright T waves V1-V3 
 ST-segment elevation in lead V4R 
 ST-segment elevation in lead V1 




 Deep ST-segment depression in lateral leads (I + aVL ≥ 2 mm & ST depression aVL 
> I) 
 QRS prolongation or epsilon wave in lead V4R 
LM specific signs 
 ST-segment elevation in aVR lead 
 ST-segment depression in all leads 
 ST-elevation in lead aVR ≥V1 
 ‘Shark-fin’ – triangular waveform ECG pattern 
Other high-risk signs 
 New RBBB 
 Myocardial infarction on previous LBBB using Scarbossa criteria 
 AV conduction abnormalities  
AV; atrioventricular, ECG; electrocardiogram, LBBB; left bundle branch block, RBBB, right 
bundle branch block. 





















Figure 2. Left anterior descending coronary artery ECG specific signs [51] 
 
Figure 3. Left circumflex coronary artery ECG specific signs [51] 
 





Figure 4. Right coronary artery ECG specific signs [51] 
 
Figure 5. Left main coronary artery ECG specific signs [51] 
 






Figure 6. The acute coronary syndrome (ACS) spectrum using the ST-segment elevation 
myocardial infarction (STEMI) vs. non- 
STEMI paradigm primarily. The current paradigm of MI divides acute MI into STEMI and 
non-STEMI based on the electrocardiogram (ECG). Occlusion myocardial infarction (OMI) and 
nonocclusion myocardial infarction (NOMI) are possible in both STEMI 










Figure 7. The acute coronary syndrome (ACS) spectrum using the occlusion myocardial 
infarction (OMI) vs. nonocclusion myocardial infarction (NOMI) paradigm primarily. The 
proposed paradigm of MI divides acute MI into OMI and NOMI. OMI are those for whom 
thrombolytics and percutaneous coronary intervention were conceptually designed and indicated, 
but many OMI do not manifest ST-segment elevation myocardial infarction (STEMI) criteria. 
ECG = electrocardiogram. [74] 
 

